Shots:
- Sanofi to acquire Kadmon for $9.50/share in cash making a total equity value of ~ $1.9B with a premium of 79% to a closing price of $5.30 on Sept 07, 2021. The acquisition is expected to be completed in Q4’21
- The acquisition will bolster Sanofi’s transplant business with the addition of Kadmon’s Rezurock to treat patients with cGVHD. Sanofi’s transplant business already includes Thymoglobulin & Mozobil that are currently marketed in 65+ countries
- Rezurock is the US FDA approved therapy to treat cGVHD in adult & pediatric patients aged ≥12yrs. who have failed 2 prior lines of systemic therapy & is currently being evaluated in P-II trial for dcSSc
Click here to read full press release/ article | Ref: Globe Newswire | Image: Medcity News
The post Sanofi to Acquire Kadmon for ~$1.9B first appeared on PharmaShots.
